logo-loader
RNS
Avacta Group PLC

Avacta Group PLC - Result of AGM

RNS Number : 2872J
Avacta Group PLC
23 June 2026
 

AVACTA GROUP PLC AVCT Stock | London Stock Exchange

  

Result of AGM

 

 

LONDON and PHILADELPHIA - June 23, 2026 - Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, today announces that all resolutions were duly passed by shareholders at the Annual General Meeting (AGM), which was held on Monday June 22.

 

The results of the voting at the AGM are outlined in the table below and the presentation materials are available on the Company's website here.

 

 

For

Against

Withheld

Resolution

Votes

%

Votes

%

Votes

1

52,701,858

99.98%

8,684

0.02%

4,914,991

2

52,103,657

99.94%

31,899

0.06%

5,489,977

3

57,460,173

99.97%

15,205

0.03%

150,155

4

57,430,906

99.98%

13,310

0.02%

181,317

5

57,427,007

99.98%

14,310

0.02%

184,216

6

57,442,445

99.98%

11,871

0.02%

171,217

7

55,827,845

97.19%

1,612,782

2.81%

184,906

8

57,318,857

99.98%

11,486

0.02%

295,190

9

57,455,176

99.98%

9,947

0.02%

160,410

10

56,788,798

99.69%

177,925

0.31%

658,810

11

56,516,332

99.22%

446,550

0.78%

662,651

12

56,524,420

99.23%

436,265

0.77%

664,848

13

57,104,150

99.55%

258,807

0.45%

262,576

 

 

 

 

-Ends-

 

For further information from Avacta, please contact:

 

Avacta Group plc

Christina Coughlin, Chief Executive Officer

https://avacta.com/

via Cohesion Bureau




Strand Hanson Limited (Nominated Adviser)

James Harris / Chris Raggett / James Dance

 

 

www.strandhanson.co.uk

 

Zeus (Broker)

James Hornigold / George Duxberry / Dominic King

 

 

www.zeuscapital.co.uk

Cohesion Bureau

Communications / Media / Investors

Richard Jarvis

 

 

avacta@cohesionbureau.com

 

 

About Avacta - https://avacta.com/

Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies through its proprietary pre|CISION® platform. pre|CISION® is a payload delivery system based on a tumor-specific protease (Fibroblast Activation Protein or FAP) that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues. Avacta's innovative pre|CISION® peptide drug conjugates (PDC) are a novel entry to the XDC drug class, leveraging the success of antibody drug conjugates with alternative methods of delivery beyond antibodies. 

 

Our pre|CISION® PDCs leverage this tumor-specific release mechanism to provide unique benefits over traditional antibody drug conjugates, releasing active payload in the tumor and reducing systemic exposure and toxicity which enables dosing to be optimized to deliver the best outcomes for patients. The lead clinical program is faridoxorubicin (AVA6000), a Gen One FAP-enabled pre|CISION® version of doxorubicin that delivers the payload directly in the tumor with limited peripheral blood exposure and has demonstrated preliminary activity in tumor types sensitive to doxorubicin including salivary gland cancer and soft tissue sarcoma. 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGEANKAAAKKEFA
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not registered in any category of registration under the securities legislation of any province or territory of Canada. Nothing in this record constitutes "advice" concerning investing in, buying, or selling a security within the meaning of applicable Canadian securities legislation. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after obtaining advice from a registrant authorised under the securities legislation of your province or territory.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship is for news distribution and media services only and does not determine, influence, or shape the editorial content produced.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

3 min read